From: Genetics of blood malignancies among Iranian population: an overview
STUDY (ET AL) | Year | Type | Gene | population | Results | Prediction |
---|---|---|---|---|---|---|
izadifar [27] | 2018 | AML | PVT1 | 134 patients 40 controls | Over expression in AML-M3 | Diagnosis |
pashaiefar [28] | 2018 | AML | IRAIN | 64 patients 51 controls | Under expression. | Poor prognosis |
ahmadi [29] | 2018 | CLL | MALAT1 | 30 patients 30 controls | Over expression. | Diagnosis |
bahari [30] | 2018 | ALL | PAX8-AS1 | 110 patients 120 controls | Polymorphism was correlated with tumor progression. | Diagnosis |
hashemi [31] | 2016 | ALL | Lnc-LAMC2 | 110 patients 120 controls | Polymorphism was correlated with tumor progression. | Diagnosis |
koolivand [32] | 2018 | AML | miR-155 | 25 patients 25 controls | Over expression. | Poor prognosis |
fathullahzadeh [33] | 2016 | CLL | miR-192 | 20 patients 20 controls | Under expression. | Diagnosis |
hashemi [34] | 2016 | ALL | miR-34b/c | 110 patients 120 controls | Polymorphism was correlated with tumor progression. | Diagnosis |
fallah [35] | 2015 | CML | miR-155, miR-106, miR-16-1, miR-15a, miR-101, and miR-568 | 50 patients | MiR-155 and miR-106 under expressions. MiR-16-1, miR-15a, miR-101, and miR-568 over expressions. | Diagnosis and prognosis |
seyyedi [36] | 2016 | AML | miR-1, miR-486, and let-7a | 45 patients | Over expressions. | Diagnosis |
hasani [37] | 2014 | ALL | miR-146a | 75 patients 115 controls | Polymorphism was correlated with tumor progression. | Diagnosis |
hashemi [38] | 2017 | ALL | DROSHA | 75 patients 115 controls | Polymorphism was correlated with tumor progression. | Diagnosis |
farzaneh [39] | 2016 | CLL and ALL | DICER | 51 patients 29 controls | Under expression. | Diagnosis |
rahmani [40] | 2017 | ALL | DNMT1 | 45 patients | Methylation. | Poor prognosis |
allahbakhshian [41] | 2018 | ALL | IL-6 and IFN-γ | 52 patients 13 controls | IFN-γ under expression in ALL. IL-6 under expression in T-ALL. | Diagnosis |
ghavami [42] | 2018 | ALL | IL-27 | 200 patients 210 controls | Polymorphism was correlated with tumor progression. | Poor prognosis |
kouzegaran [43] | 2018 | CLL | IL-17A and IL-22 | 78 patients 28 controls | Over expressions. | Diagnosis |
sepehrizadeh [44] | 2014 | AML | IL-1β, IL-8, IL-10, and IFN-γ | 46 patients | IL-1β, IL-8, and IL-10 under expressions after chemotherapy. IFN-γ over expression after chemotherapy. | Diagnosis |
amirzargar [45] | 2005 | CML | TGF-β, IL-4, and IL-10 | 30 patients 40 controls | TGF-β over expression. IL-4 and IL-10 under expressions. | Diagnosis |
abdolmaleki [46] | 2018 | AML | PD-1 and CD244 | 30 patients 15 controls | Over expressions. | Diagnosis |
taghiloo [47] | 2017 | CLL | GAL-9 and PD-L1 | 25 patients 15 controls | Over expressions. | Poor prognosis |
amirghofran [48] | 2001 | AML | CD11b | 70 patients | Correlation with survival. | Diagnosis |
ramzi [49] | 2018 | AML, ALL, CML | CTLA-4, CD28, and PD-1 | 59 patients 46 controls | Polymorphisms were correlated with tumor progression. | Diagnosis |
nasiri [50] | 2013 | ALL, NHL | TNF-α and LT-α | 138 patients 130 controls | Polymorphisms were correlated with tumor progression. | Diagnosis |
orouji [51] | 2012 | ALL | HLA-D | 135 patients 150 controls | Allele frequencies were correlated with tumor progression. | Diagnosis |
rezvany [52] | 2007 | CLL | HLA-G | 74 patients 12 controls | Over expression. | Diagnosis |
amirzargar [53] | 2007 | CML | HLA-D | 50 patients 80 controls | Allele frequencies were correlated with tumor progression. | Diagnosis |
khosravi [54] | 2007 | CML | HLA-D | 50 patients 180 controls | Allele frequencies were correlated with tumor progression. | Diagnosis |
sarafnejad [55] | 2006 | AML | HLA-D | 60 patients 180 controls | Allele frequencies were correlated with tumor progression. | Diagnosis |
moazzeni [56] | 1999 | CLL | HLA-B and HLA-D | 32 patients | Allele frequencies were correlated with tumor progression. | Diagnosis |
shahsavar [57] | 2010 | AML and ALL | KIR2DS3 | 78 patients 200 controls | Genotype frequencies were correlated with tumor progression. | Diagnosis |
noori-daloii [58] | 2013 | GVHD | IL-1α, IL-4Rα, and IL-12 | 91 patients | Polymorphisms were correlated with tumor progression. | Good prognosis |
kazemi [59] | 2009 | ALL | FCRL1–5 | 73 patients 35 controls | Under expressions. | Diagnosis |
pouyanrad [60] | 2019 | ALL | miR-335-5p | 64 patients 30 controls | Under expression. | Poor prognosis |
rahgozar [61] | 2014 | ALL | ABCA3, ABCA2, MRD1, and MRP1 | 27 patients 15 controls | Were correlated with drug resistance. | Poor prognosis |
mahjoubi [62] | 2008 | AML and ALL | MRP1 | 52 patients 10 controls | Correlation with poor clinical outcomes. | Poor prognosis |
mahjoubi [63] | 2012 | ALL | MRP1 | 42 patients 10 controls | Over expression. | Poor prognosis |
ghodousi [64] | 2018 | ALL | miR-326 and miR-200c | 46 patients 16 controls | Under expressions. | Poor prognosis |
mesrian tanha [65] | 2017 | ALL | ABCC4 | 145 patients | Polymorphism was correlated with tumor progression. | Poor prognosis |
kazemi [66] | 2018 | Leukemia | HO-1 | 63 patients | Genotype frequencies were correlated with tumor progression. | Good prognosis |
saadat [67] | 2000 | ALL | GSTM1 | 38 patients 75 controls | Allele frequencies were correlated with tumor progression. | Diagnosis |
seghatoleslam [68] | 2014 | ALL | UBE2Q1 | 20 patients 20 controls | Under expression. | Diagnosis |
seghatoleslam [69] | 2012 | ALL | UBE2Q2 | 20 patients 20 controls | Over expression. | Diagnosis |
zareifar [70] | 2018 | AML | Livin and BIRC5 | 43 patients | Correlation with poor prognosis. | Poor prognosis |
rostami [71] | 2017 | AML | APAF1 | 101 patients 50 controls | Methylation. | Diagnosis |
asgarian-omran [72] | 2010 | CLL | GAL-3 | 85 patients | Under expression. | Poor prognosis |
daneshbod [73] | 2005 | AML | BCL-2 | 70 patients | Correlation with survival. | Poor prognosis |
zare-abdollahi [74] | 2016 | AML | BECN1 | 128 patients | Under expression. | Prognosis |
amirghofran [75] | 2009 | ALL | BCL-2 | 50 patients | Correlation with poor prognosis. | Poor prognosis |
younesian [76] | 2017 | ALL | RASSF6 | 45 patients | Methylation. | Poor prognosis |
pashaiefar [77] | 2018 | AML | PARP1 | 65 patients 54 controls | Over expression. | Poor prognosis |
pashaiefar [78] | 2018 | AML | PARP1 | 78 patients 19 controls | Over expression. | Poor prognosis |
bahari [79] | 2016 | ALL | MTHFR | 100 patients 120 controls | Polymorphism was correlated with tumor progression. | Diagnosis |
bahari [80] | 2016 | ALL | SHMT1 | 120 patients 120 controls | Polymorphism was correlated with tumor progression. | Diagnosis |
bahari [81] | 2017 | ALL | FHIT | 100 patients 120 controls | Methylation. | Diagnosis |
kamali dolatabadi [82] | 2017 | AML | CDKN2B | 59 patients | Methylation. | Diagnosis |
memarian [83] | 2012 | ALL | WNT-7B, WNT-9A, WNT-16B, WNT-2B, WNT-5A, WNT-7A, WNT-10A | 71 patients 36 controls | WNT-7B, WNT-9A, and WNT-16B over expressions. WNT-2B, WNT-5A, WNT-7A, and WNT-10A under expressions. | Diagnosis |
memarian [84] | 2009 | CLL | WNT-3, WNT-4, WNT-5B, WNT-7B, WNT-9A, WNT-10A, WNT-16B, WNT-7A | 62 patients 11 controls | WNT-3, WNT-4, WNT-5B, WNT-7B, WNT-9A, WNT-10A, and WNT-16B over expressions. WNT-7A under expression. | Diagnosis |
memarian [85] | 2007 | AML | WNT-3, WNT-7A, Wnt-10A | 16 patients 36 controls | WNT-3 over expression. WNT-7A and Wnt-10A under expressions. | Diagnosis |
ghasemi [86] | 2015 | AML | SFRP1, SFRP2 | 43 patients 25 controls | Methylation. | Diagnosis |
gholami [87] | 2014 | AML | LATS2 | 32 patients 10 controls | Over expression. | Poor prognosis |
rafiee [88] | 2016 | AML | RSK4 | 40 patients 10 controls | Under expression. | Poor prognosis |
salarpour [89] | 2017 | AML | CEBPA, RUNX-1 | 96 patients 18 controls | CEBPA and RUNX-1 over expressions. | Diagnosis |
ayatollahi [90] | 2017 | AML | WT1 | 126 patients | Over expression. | Diagnosis |
rezai [91] | 2015 | Leukemia | WT1 | 12 patients 12 controls | Over expression. | Diagnosis |
asgarian omran [92] | 2008 | ALL | WT1 | 116 patients 36 controls | Over expression. | Diagnosis |
bahari [93] | 2016 | ALL | IKZF1 | 110 patients 120 controls | Polymorphism was correlated with tumor progression. | Diagnosis |
rezaei [94] | 2017 | AML | FLT3, NPM1 | 70 patients | Mutation. | Diagnosis |
nasiri [95] | 2014 | AML | FLT3 | 27 patients | Mutation. | Diagnosis |
pazhakh [96] | 2011 | AML | NPM1 | 131 patients | Mutation. | Diagnosis |
zaker [97] | 2010 | AML | FLT3, KIT | 212 patients | Mutation. | Diagnosis |
jafari ghahfarokhi [98] | 2014 | CLL | ZAP70 | 66 patients | Over expression. | Good prognosis |
shabani [99] | 2008 | ALL | ROR1, WT1 | 51 patients | Over expressions. | Diagnosis |
aliparasti [100] | 2013 | AML | VEGF-C | 27 patients 28 controls | Under expression. | Diagnosis |
amirpour [101] | 2016 | AML | BAALC | 47 patients 47 controls | Over expression. | Poor prognosis |
nadimi [102] | 2016 | ALL, AML | BAALC | 145 patients | Polymorphism was correlated with tumor progression. | Poor prognosis |
mobasheri [103] | 2006 | ALL | TSGA10 | 52 patients | Expression in ALL cases. | Diagnosis and prognosis |
hoseinkhani [104] | 2019 | AML | TSGA10, HIF-1α | 30 patients 10 controls | TSGA10 under expression. HIF-1α over expression. | Diagnosis |